A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors
An Observational Parallel Group Phase 4 Study to Determine Progression-Free Survival and Evaluate Patient Experience for Patients With Metastatic ALK+ Non-Small Cell Lung Cancer (NSCLC) Treated With ALK Inhibitors
Sponsor: Takeda
This observational or N/A phase trial investigates Anaplastic Lymphoma Kinase-positive and Carcinoma Non-small-cell Lung and is currently completed. Takeda leads this study, which shows 13 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Aug 2024 — Sep 2024 [monthly]
Completed
-
Jul 2024 — Aug 2024 [monthly]
Completed
-
Dec 2023 — Jul 2024 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Sep 2023 — Dec 2023 [monthly]
Active Not Recruiting
▶ Show 8 earlier versions
-
Apr 2022 — Sep 2023 [monthly]
Active Not Recruiting
-
Sep 2021 — Apr 2022 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — Sep 2021 [monthly]
Recruiting
-
Aug 2020 — Jan 2021 [monthly]
Recruiting
-
Aug 2019 — Aug 2020 [monthly]
Recruiting
-
Oct 2018 — Aug 2019 [monthly]
Recruiting
-
Sep 2018 — Oct 2018 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Jul 2018 — Sep 2018 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Takeda
For direct contact, visit the study record on ClinicalTrials.gov .